ALPS Advisors’s ImmunityBio IBRX Stock Holding History

ALPS Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-106,549	Closed	-$414K	–	946
2018 Q1	$414K	Buy	106,549 +18,519	+21%	+$81.2K	﹤0.01%	784
2017 Q4	$395K	Buy	88,030 +9,793	+13%	+$46.4K	﹤0.01%	682
2017 Q3	$429K	Buy	78,237 +4,081	+6%	+$25.1K	﹤0.01%	684
2017 Q2	$563K	Buy	+74,156	New	+$320K	﹤0.01%	396

Other funds holding IBRX

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

ALPS Advisors's IBRX Position: Q2 2018 in Review

ALPS Advisors sold out of ImmunityBio (IBRX) in Q2 2018, closing a stake of 106,549 shares — an estimated $414K sold.

ALPS Advisors first reported a position in IBRX in Q2 2017 and held it in 4 quarters. The position peaked at $563K in Q2 2017. 64 funds tracked by Wall St. Rank hold IBRX as of Q2 2018.

ALPS Advisors reported no remaining ImmunityBio position as of Q2 2018 after selling out during the quarter.
ALPS Advisors sold 106,549 ImmunityBio shares in Q2 2018, an estimated $414K.
ALPS Advisors first reported a position in ImmunityBio in Q2 2017 and held it in 4 quarters.
ALPS Advisors's ImmunityBio position peaked at $563K in Q2 2017.
64 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2018.

Based on ALPS Advisors's 13F filing for Q2 2018, filed 25 Jul 2018.